Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
Open Access
Abstract
Precision medicine aims to implement strategies based on the molecular features of tumors and optimized drug delivery to improve cancer diagnosis and treatment. DNA replication is a logical approach because it can be targeted by a broad range of anticancer drugs that are both clinically approved and in development. These drugs increase deleterious replication stress (RepStress); however, how to selectively target and identify the tumors with specific molecular characteristics are unmet clinical needs. Here, we provide background information on the molecular processes of DNA replication and its checkpoints, and discuss how to target replication, checkpoint, and repair pathways with ATR inhibitors and exploit Schlafen 11 (SLFN11) as a predictive biomarker.Keywords
Funding Information
- National Cancer Institute (BC-006150)
This publication has 153 references indexed in Scilit:
- Ciprofloxacin is an inhibitor of the Mcm2-7 replicative helicaseBioscience Reports, 2013
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsProceedings of the National Academy of Sciences, 2012
- Small-Molecule Targeting of Proliferating Cell Nuclear Antigen Chromatin Association Inhibits Tumor Cell GrowthMolecular Pharmacology, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated agingNature Genetics, 2009
- Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage ResponseJournal of Biological Chemistry, 2009
- γH2AX and cancerNature Reviews Cancer, 2008
- Replication licensing and cancer — a fatal entanglement?Nature Reviews Cancer, 2008